Loading
Donor immune cells that need no matching could be given as short courses to clear the few cancer cells left after surgery, when the target is smallest.
Allogeneic natural killer and CAR-NK products have been limited by short persistence and modest activity against bulky solid tumours, but persistence matters far less when the target is a handful of disseminated cells. Combined with a cytokine support agent, repeat dosing in the molecular residual disease window is a rational use of a product class that has struggled in advanced disease.
Shares Fate Therapeutics, CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines.
Shares Fate Therapeutics, CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
Shares ImmunityBio, Nogapendekin alfa inbakicept.
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Triple-negative breast cancer (TNBC).
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Triple-negative breast cancer (TNBC).
Shares Dormant cells and minimal residual disease, Manufacturing cost and time for living and radioactive medicines, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares ImmunityBio, Nogapendekin alfa inbakicept.
Shares ImmunityBio, Nogapendekin alfa inbakicept.